New Competition, Procedure Declines Challenge Abbott Vascular In Second Quarter
This article was originally published in The Gray Sheet
Executive Summary
Abbott’s stent business was up against an approximately 5% decline in U.S. percutaneous coronary intervention procedures in the past quarter, on top of persistent pricing pressures and the U.S. launch earlier this year of Medtronic’s Resolute Integrity.